JANX icon

Janux Therapeutics

56.14 USD
-0.61
1.07%
At close Dec 24, 4:00 PM EST
After hours
56.14
+0.00
0.00%
1 day
-1.07%
5 days
-5.44%
1 month
14.99%
3 months
15.56%
6 months
29.89%
Year to date
409.44%
1 year
437.74%
5 years
123.22%
10 years
123.22%
 

About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Employees: 76

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

22% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 27

4% more funds holding

Funds holding: 153 [Q2] → 159 (+6) [Q3]

2% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 51

1.69% less ownership

Funds ownership: 89.14% [Q2] → 87.46% (-1.69%) [Q3]

25% less capital invested

Capital invested by funds: $2.77B [Q2] → $2.07B (-$701M) [Q3]

86% less call options, than puts

Call options by funds: $4.14M | Put options by funds: $29.8M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$62
10%
upside
Avg. target
$101
80%
upside
High target
$200
256%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Cantor Fitzgerald
Josh Schimmer
37% 1-year accuracy
22 / 59 met price target
256%upside
$200
Overweight
Reiterated
11 Dec 2024
Scotiabank
George Farmer
20% 1-year accuracy
4 / 20 met price target
10%upside
$62
Sector Perform
Maintained
4 Dec 2024
Stifel
Bradley Canino
18% 1-year accuracy
6 / 33 met price target
105%upside
$115
Buy
Maintained
3 Dec 2024
Leerink Partners
Jeffrey La Rosa
33% 1-year accuracy
1 / 3 met price target
62%upside
$91
Outperform
Maintained
3 Dec 2024
HC Wainwright & Co.
Swayampakula Ramakanth
27% 1-year accuracy
46 / 173 met price target
25%upside
$70
Buy
Maintained
3 Dec 2024

Financial journalist opinion

Based on 10 articles about JANX published over the past 30 days

Neutral
Business Wire
2 weeks ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of.
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Neutral
Business Wire
2 weeks ago
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas.
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Positive
The Motley Fool
2 weeks ago
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.
Why Janux Therapeutics Crushed the Market Today
Positive
Zacks Investment Research
3 weeks ago
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
JANX Stock Hits Record High on Prostate Cancer Study Data
Neutral
Business Wire
3 weeks ago
Janux Therapeutics Announces Proposed Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering.
Janux Therapeutics Announces Proposed Public Offering
Positive
Benzinga
3 weeks ago
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
On Monday, Janux Therapeutics, Inc.  JANX revealed updated interim clinical data for its JANX007 clinical program.
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Positive
Barrons
3 weeks ago
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment.
Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results
Positive
Investors Business Daily
3 weeks ago
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Shares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment. The post Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients appeared first on Investor's Business Daily.
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Neutral
Business Wire
3 weeks ago
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC.
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Neutral
Business Wire
4 weeks ago
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
Charts implemented using Lightweight Charts™